Cambrex expands manufacturing in Sweden
- Cambrex, a manufacturer of small molecules and active pharmaceutical ingredients, said earlier this week it is investing $9 million to expand its large-scale manufacturing capacity at a facility in Karlskoga, Sweden.
- The money the New Jersey-based company is investing will go to new multi-purpose reactors and upgrading the control room for the existing plant on site.
- The new facility is expected to open in the fourth quarter and will subsequently undergo validation and cGMP qualification.
"Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities," said Bjarne Sandberg, managing director of the Cambrex Karlskoga facility.
Cambrex noted the Swedish site expansion is part of an ongoing campaign the company has been undertaking to increase its active pharmaceutical ingredient manufacturing capacity.
The company previously announced investments in its Charles City, Iowa facility, reported In-Pharma Technologist, which were projected to cost $20 million.
- Cambrex Press Release
- In-Pharma Technologist Cambrex to start work on Pharma 4 API site in 2016
Follow Lisa LaMotta on Twitter